Humacyte Inc [HUMA] stock is trading at $1.53, up 33.04%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The HUMA shares have gain 4.79% over the last week, with a monthly amount drifted -49.00%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Humacyte Inc [NASDAQ: HUMA] stock has seen the most recent analyst activity on December 20, 2024, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $15 from $12. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 11, 2023, and set its price target to $6. On August 14, 2023, upgrade upgraded it’s rating to Neutral and revised its price target to $3.50 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $6 on June 22, 2023. Piper Sandler downgraded its rating to a Underweight and reduced its price target to $4 on May 16, 2022. Cowen started tracking with a Outperform rating for this stock on October 29, 2021, and assigned it a price target of $17. In a note dated September 24, 2021, Oppenheimer initiated an Outperform rating and provided a target price of $16 on this stock.
Humacyte Inc [HUMA] stock has fluctuated between $1.15 and $9.97 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Humacyte Inc [NASDAQ: HUMA] shares were valued at $1.53 at the most recent close of the market. An investor can expect a potential return of 422.88% based on the average HUMA price forecast.
Analyzing the HUMA fundamentals
Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2800 points at the first support level, and at 1.0300 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6600, and for the 2nd resistance point, it is at 1.7900.
Ratios To Look Out For
For context, Humacyte Inc’s Current Ratio is 2.40. Further, the Quick Ratio stands at 2.40, while the Cash Ratio is 2.25.
Transactions by insiders
Recent insider trading involved Sebelius Kathleen, Director, that happened on Apr 08 ’25 when 50000.0 shares were purchased. Director, Green Charles Bruce completed a deal on Apr 08 ’25 to buy 6000.0 shares. Meanwhile, Director Constantino Michael T. bought 16000.0 shares on Apr 07 ’25.
